The Biotinylated Anti-CD123 Antibody (HDLA005) is a valuable tool for researchers studying CD123, a cell surface marker commonly found on leukemic stem cells in acute myeloid leukemia (AML) and other hematologic malignancies. This antibody, produced using advanced biotinylation technology, is highly specific and sensitive for detecting CD123 in human samples. It is suitable for various applications, including immunofluorescence, flow cytometry, and immunohistochemistry.
CD123, also known as interleukin-3 receptor alpha chain, is an attractive target for therapeutic development due to its selective expression on leukemic cells and leukemic stem cells. By targeting CD123, researchers aim to develop more effective treatments for AML and other CD123-expressing cancers. The Biotinylated Anti-CD123 Antibody provides a reliable tool for investigating CD123 biology and developing novel targeted therapies for cancer.
Purified from cell culture supernatant by affinity chromatography
Formulation:
Powder
Buffer:
1XPBS
Storage:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Usage:
Research use only
Background:
Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.
